-Retrospective analysis presented at the 34 th International Conference on Pharmacoepidemiology & Therapeutic Risk Management - CAMPBELL, Calif. , Aug. 27, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, has reported encouraging data from a
-Favorable pharmacokinetic results add to body of data supporting continued development in the treatment of pulmonary arterial hypertension- CAMPBELL, Calif. , July 10, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, today announced positive
CAMPBELL, Calif. , June 11, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, today announced that it has met the closing conditions, including Hart-Scott-Rodino review, related to the Company’s previously announced acquisition of U.S.
Attains key milestone under strategic focus on building a broad portfolio of cash flow-generating products CAMPBELL, CA., May 1, 2018 – VIVUS, Inc. (N asdaq : VVUS; the “Company”), a biopharmaceutical company, today announced that it has entered into a definitive agreement to acquire all product
Board Member Thomas B. King appointed interim CEO; Seth Fischer steps down as CEO effective December 31, 2017 CAMPBELL, CA -- (Marketwired) -- 12/26/17 -- VIVUS, Inc. (NASDAQ: VVUS) today announced that it has reached agreement with Seth H. Z. Fischer pursuant to which he will step down as chief
CAMPBELL, CA -- (Marketwired) -- 09/06/17 -- VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced that the European
CAMPBELL, CA , and SAN GWANN, MALTA -- (Marketwired) -- 09/05/17 -- VIVUS, Inc. (NASDAQ: VVUS) and Alvogen Malta Operations (ROW) Ltd , today announced an agreement under which Alvogen will market Qsymia ® (phentermine and topiramate extended-release) in the Republic of Korea for the treatment of
CAMPBELL, CA -- (Marketwired) -- 08/30/17 -- VIVUS, Inc. (NASDAQ: VVUS) announced today that it has entered into a settlement agreement with Dr. Reddy's Laboratories, S.A. and Dr. Reddy's Laboratories, Inc. (Dr. Reddy's) resolving patent litigation related to Qsymia® (phentermine and topiramate
CAMPBELL, CA -- (Marketwired) -- 07/05/17 -- VIVUS, Inc. (NASDAQ: VVUS) announced today that it has entered into a settlement agreement with Actavis Laboratories FL (Actavis) resolving patent litigation related to Qsymia® (phentermine and topiramate extended-release) capsules CIV.
